Gamma Glutamyl Transferase as a Predictor in Acute Coronary Syndrome
DOI:
https://doi.org/10.52783/jns.v14.1736Keywords:
acute coronary syndrome, gamma-glutamyl transferase, cardiac events.Abstract
Background: Acute coronary syndrome (ACS) is a leading cause of morbidity and mortality in India. Serum gamma-glutamyl transferase (GGT) has been associated with atherosclerosis-related ACS and coronary artery calcification.
Objectives: The study is to determine the correlation between acute myocardial infarction and serum gamma-glutamyl transferase.
Materials and Methods: This study was conducted with meticulous care, adhering to a cross-sectional observational design. It involved a comprehensive examination of 50 ACS patients aged 30 to 80, with exclusions made for alcohol users, hepatitis B/C patients, those on hepatotoxic drugs, and other GGT-elevating conditions. This rigorous approach ensures the reliability and validity of our findings.
Results: The mean age was 58.12 years, with a majority being males. The mean GGT level was 73.7 IU/L. Significant associations were found between GGT levels and vessel involvement, plaque size, and ACS types. Patients with ST-elevation myocardial infarction (STEMI) had higher GGT levels compared to those with non-ST elevation myocardial infarction (NSTEMI) and unstable angina.
Conclusion: GGT is significantly associated with ACS, particularly in STEMI patients.
Downloads
Metrics
References
Zègre-Hemsey, J. K., Asafu-Adjei, J., Fernandez, A., & Brice, J. (2019). Characteristics of prehospital electrocardiogram use in North Carolina using a novel linkage of emergency medical services and emergency department data. Prehospital Emergency Care, 23(6), 772-779.
Greenland, P., Knoll, M. D., Stamler, J., Neaton, J. D., Dyer, A. R., Garside, D. B., et al. (2003). Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA, 290, 891-7.
Khot, U. N., Khot, M. B., Bajzer, C. T., Sapp, S. K., Ohman, E. M., Brener, S. J., et al. (2003). Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 290, 898-904.
Srinath Reddy, K., Shah, B., Varghese, C., & Ramadoss, A. (2005). Responding to the threat of chronic diseases in India. Lancet, 366, 1744–1749. https://doi.org/10.1016/S0140-6736(05)67343-6.
Joshi, P., Islam, S., Pais, P., Reddy, S., Dorairaj, P., Kazmi, K., Pandey, M. R., Haque, S., Mendis, S., Rangarajan, S., & Yusuf, S. (2007). Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA, 297, 286–294.
Xavier, D., Pais, P., Devereaux, P. J., Xie, C., Prabhakaran, D., Reddy, K. S., Gupta, R., Joshi, P., Kerkar, P., Thanikachalam, S., Haridas, K. K., Jaison, T. M., Naik, S., Maity, A. K., & Yusuf, S.; CREATE registry investigators. (2008). Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet, 371, 1435–1442.
Yusuf, S., Rangarajan, S., Teo, K., Islam, S., Li, W., Liu, L., Bo, J., Lou, Q., Lu, F., Liu, T., Yu, L., Zhang, S., Mony, P., Swaminathan, S., Mohan, V., Gupta, R., Kumar, R., Vijayakumar, K., Lear, S., Anand, S., Wielgosz, A., Diaz, R., Avezum, A., Lopez- Jaramillo, P., Lanas, F., Yusoff, K., Ismail, N., Iqbal, R., Rahman, O., Rosengren, A., Yusufali, A., Kelishadi, R., Kruger, A., Puoane, T., Szuba, A., Chifamba, J., Oguz, A., McQueen, M., McKee, M., & Dagenais, G.; PURE Investigators. (2014). Cardiovascular risk and events in 17 low-, middle-, and high-income countries. New England Journal of Medicine, 371, 818–827.
Prabhakaran, D., Yusuf, S., Mehta, S., Pogue, J., Avezum, A., Budaj, A., Cerumzynski, L., Flather, M., Fox, K., Hunt, D., Lisheng, L., Keltai, M., Parkhomenko, A., Pais, P., Reddy, S., Ruda, M., Hiquing, T., & Jun, Z. (2005). Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. Indian Heart Journal, 57, 217–225.
Patel, V., Chatterji, S., Chisholm, D., Ebrahim, S., Gopalakrishna, G., Mathers, C., Mohan, V., Prabhakaran, D., Ravindran, R. D., & Reddy, K. S. (2011). Chronic diseases and injuries in India. Lancet, 377, 413–428. https://doi.org/10.1016/S0140- 6736(10)61188-9.
Bauer, M., Caviezel, S., Teynor, A., et al. (2012). Carotid intima media thickness as a biomarker of subclinical atherosclerosis. Swiss Medical Weekly, 142, w13705. https://doi.org/10.4414/smw.2012.13705.
Desai, C. S., Ning, H., Kang, J., et al. (2013). Competing cardiovascular outcomes associated with subclinical atherosclerosis (from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 111, 1541–1546. https://doi.org/10.1016/j.amjcard.2013.01.306.
Hassan, A., Nazir, S. A., & Alkadhi, H. (2011). Technical challenges of coronary CT angiography: today and tomorrow. European Journal of Radiology, 79, 161–171. https://doi.org/10.1016/j.ejrad.2010.09.009.
Soon, K., & Wong, C. (2012). Coronary computed tomography angiography: a new wave of cardiac imaging. Internal Medicine Journal, 42(suppl 5), 22–29.
Min, J. K., Shaw, L. J., Devereux, R. B., et al. (2007). Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. Journal of the American College of Cardiology, 50, 1161–1170.
Brenner, H., Rothenbacher, D., Arndt, V., Schuberth, S., Fraisse, E., & Fliedner, T. M. (1997). Distribution, determinants, and prognostic value of gammaglutamyltranspeptidase for all-cause mortality in a cohort of construction workers from south Germany. Preventive Medicine, 26, 305–10.
Wannamethee, G., Ebrahim, S., & Shaper, A. G. (1995). Gammaglutamyl transferase: Determinants and association with mortality from ischemic heart disease and all causes. American Journal of Epidemiology, 142, 699–708.
Peterson, B., Trell, E., Kristensson, H., Fex, G., Yettra, M., & Hood, B. (1983). Comparison of gammaglutamyltransferase and other health screening tests in average middle-aged males, heavy drinkers, and alcohol non-users. Scandinavian Journal of Clinical and Laboratory Investigation, 43, 141–9.
Mason, J. E., Starke, R. D., & Van Kirk, J. E. (2010). Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Preventive Cardiology, 13, 36–41.
Turgut, O., Tandogan, I., & Gurlek, A. (2009). Association of gammaglutamyltransferase with cardiovascular risk: a prognostic outlook. Archives of Medical Research, 40, 318–320.
Emdin, M., Passino, C., Michelassi, C., et al. (2009). Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. International Journal of Cardiology, 136, 80–85.
Celik, O., Cakmak, H. A., Satilmis, S., Gungor, B., Akin, F., & Ozturk, D., et al. (2014). The relationship between gamma-glutamyl transferase levels and coronary plaque burdens and plaque structures in young adults with coronary atherosclerosis. Clinical Cardiology, 37(9), 552–557.
Kalifa, M., Revathi, A., Nithyakalyani, R., Sivanesan, K. R., & Anandraj, J. (2021). Study on association of gamma glutamyl transferase with acute coronary syndrome and correlation with in-hospital outcome. IAIM, 8(1), 70-77.
Singh, K. K., Kapoor, A., Khanna, R., Sahu, A., Kapoor, V., & Kumar, S., et al. (2022). Serum gamma-glutamyltransferase (GGT) in coronary artery disease: exploring the Asian Indian connection. Annals of Cardiac Anaesthesia, 25, 408-13.
Dogan, A., Icli, A., Aksoy, F., Varol, E., Erdogan, D., Ozaydin, M., & Kocyigit, S. (2012). Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coronary Artery Disease, 23(1), 39-44.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
